Today, the Cystic Fibrosis Foundation announced a collaboration with Deep Science Ventures to accelerate treatments that address the underlying cause of CF for every person with the disease. The collaboration will focus on uncovering and designing new technologies to address key scientific challenges on the Path to a Cure.
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
June 13, 2021
|
4 min read
New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations
May 27, 2021
|
5 min read
Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide therapy for people with cystic fibrosis who have splicing mutations and potentially other rare mutations.
May 13, 2021
|
4 min read
The Cystic Fibrosis Foundation recently submitted comments to the National Institutes of Health on improving racial equity, diversity, and inclusion in the biomedical research workforce.
April 15, 2021
|
2 min read
William Skach, MD, Chief Scientific Officer, will retire from the CF Foundation this summer.
March 31, 2021
|
2 min read
The Cystic Fibrosis Foundation has renewed its commitment to supporting the health and well-being of adults living with cystic fibrosis by supporting free access to the online exercise, education, and well-being platform, Beam.
March 9, 2021
|
3 min read
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.
Feb. 16, 2021
|
4 min read
The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat multi-drug resistant Pseudomonas and other infections in people with cystic fibrosis.
Jan. 26, 2021
|
3 min read
The Cystic Fibrosis Foundation announced a new set of research agreements to drive progress on its Path to a Cure. The nine awards will advance a variety of tools and strategies to accelerate treatments for the underlying cause of cystic fibrosis for all people with CF, regardless of their mutations.
Dec. 10, 2020
|
4 min read